Advertisement
Research Article

Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide

  • Eric L Snyder,

    Affiliations: Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America, Washington University School of Medicine, St. Louis, Missouri, United States of America

    X
  • Bryan R Meade,

    Affiliation: Department of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, California, United States of America

    X
  • Cheryl C Saenz,

    Affiliations: Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America, Department of Reproductive Medicine, School of Medicine, University of California, San Diego, La Jolla, California, United States of America

    X
  • Steven F Dowdy mail

    To whom correspondence should be addressed. E-mail: sdowdy@ucsd.edu

    Affiliations: Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America, Department of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, California, United States of America

    X
  • Published: February 17, 2004
  • DOI: 10.1371/journal.pbio.0020036

About the Authors

Eric L Snyder, Cheryl C Saenz, Steven F Dowdy
Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America
Eric L Snyder
Washington University School of Medicine, St. Louis, Missouri, United States of America
Bryan R Meade, Steven F Dowdy
Department of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, California, United States of America
Cheryl C Saenz
Department of Reproductive Medicine, School of Medicine, University of California, San Diego, La Jolla, California, United States of America

Corresponding Author

Email: sdowdy@ucsd.edu

Competing Interests

SFD is the scientific founder of Ansata Therapeutics, a biotech company utilizing protein transduction technology to treat human disease. However, he owns less than 5% of the stock, does not receive any research funds from Ansata, does not have a seat on the board of directors, and has no say in the governance of the company.

Author Contributions

ELS and SFD conceived and designed the experiments. ELS, BRM, and CCS performed the experiments. CCS and SFD analyzed the data. BRM and CCS contributed reagents/materials/analysis tools. ELS and SFD wrote the paper.